Mutation screening of the EYA1, SIX1 and SIX5 genes in a large cohort of patients harboring branchio-oto-renal syndrome calls into question the pathogenic role of SIX5 mutations.
Mutations in SIX1, a DNA binding protein that associates with EYA1, have been reported less frequently. One group has recently described 4 missense mutations in SIX5 in 5 unrelated patients with BOR.
Here, we report a screening of these three genes in a cohort of 140 patients from 124 families with BOR. We identified 36 EYA1 mutations in 42 unrelated patients, 2 mutations and one change of unknown significance in SIX1 in 3 unrelated patients, but no mutation in SIX5. We did not find correlation between genotype and phenotype, and observed a high phenotypic variability between and within BOR families. We show the difficulty in establishing a molecular diagnosis strategy in BOR syndrome: the screening focusing on patients with typical BOR would detect a mutation rate of 76%, but would also miss mutations in 9% of patients with atypical BOR. We detected a deletion removing three EYA1 exons in a patient who was previously reported to carry the SIX5 Thr552Met mutation. This led us to reconsider the role of SIX5 in the development of BOR.
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Deleted: the screening of only patients with typical BOR would lead to a 76% rate of mutation detection but would also miss mutations in 9% of atypical BOR Deleted: . is characterized by hearing loss, branchial arch defects and various renal anomalies. The prevalence of BOR syndrome is estimated to be 1 case per 40 000 (Chen et al., 1995; Fraser et al., 1978; Fraser et al., 1980 , Melnick et al., 1975 , Melnick et al., 1978 . The syndrome is clinically heterogeneous and has a high penetrance with variable expressivity (Fraser et al., 1978 , Fraser et al., 1980 , Chen et al., 2004 . BOR syndrome is also genetically heterogeneous.
Over 80 mutations in EYA1 (MIM ID 601653), the human homolog of the Drosophila eyes absent gene, encoding a transcriptional regulator, have been identified. These include large and small heterozygous deletions, frameshift, stop, splice-site and missense heterozygous mutations (Abdelhak et al., 1997b , Ni et al., 1994 , Vincent et al., 1997 . The rate of detection of EYA1 mutations varies from 7% to 40% of patients tested according to the clinical criteria required for molecular testing (Abdelhak et al., 1997a , Abdelhak et al., 1997b . Mutations in SIX1 (MIM ID 601205) (mainly missense mutations and small deletions), the human homolog of sine oculis encoding a DNA binding protein that associates with EYA1, have also been associated with BOR syndrome (Kochhar et al., 2008 , Ruf et al., 2003 , Ruf et al., 2004 , Sanggaard et al., 2007 , though much less frequently than EYA1 mutations. More recently, missense mutations in another SIX family member, SIX5
(MIM ID 600963), have been reported by one group in patients with BOR syndrome (Hoskins et al., 2007) . SIX5 homologous is known to interact with eya-1 in C. elegans. In vitro functional analyses of the BOR-associated SIX5 variants showed that some of these variants modified EYA1-SIX5 binding and the ability of the EYA1-SIX5 complex to transactivate a 1  2  3  4  5  6  7  8  9  10  11  12  13  14  15  16  17  18  19  20  21  22  23  24  25  26  27  28  29  30  31  32  33  34  35  36  37  38  39  40  41  42  43  44  45  46  47  48  49  50  51  52  53  54  55  56  57  58  59 (Hoskins et al., 2007) . However, the association of SIX5 mutations with BOR syndrome has not been confirmed by other groups.
In the present study, we screen for EYA1, SIX1 and SIX5 mutations a large cohort of patients with BOR syndrome. We describe the clinical features associated with the mutations and the rate of mutations identified, according to the clinical phenotypes. We also show that one family previously reported as carrying a SIX5 missense mutation harbors a heterozygous deletion of three EYA1 exons, which therefore questions the role of the reported SIX5 change.
PATIENTS AND METHODS

Patients
A total of 140 patients from 124 families with a diagnosis of BOR syndrome were included in the study. Subjects were classified according to the criteria defined by Chang on the basis of clinical history, audiometry and renal ultrasonography. Patients were considered as typical BOR when they had at least three major criteria (branchial anomalies, deafness, preauricular pits or renal anomalies), or two major and two minor criteria (internal, middle and/or external ear anomalies, preauricular tags, facial asymmetry or palatine anomalies) or one major criterion and an affected first-degree relative meeting the above criteria for typical BOR. Other were considered as atypical BOR and were tested only when they demonstrated at least two features of the syndrome.
Patient 1062 was previously reported as carrying a heterozygous SIX5 c.1655C>T (p.Thr552Met) mutation (patient A500 in Hoskins et al.) . His DNA had been tested for EYA1 mutations by direct sequencing, but not for abnormal copy number (Hoskins et al., 2007) .
This patient was having assisted reproduction, and thus was making inquiries regarding the possibility of preimplantation genetic testing.
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Human Mutation
Mutation analysis
Genomic DNA was isolated from peripheral blood using standard methods. The 16 exons of EYA1 were screened for mutations by direct sequencing. When no mutation was found, quantitative multiplex PCR amplification of short fluorescence fragments (Charbonnier et al., 2000) was performed for EYA1 exons 1, 5, 10, 15 
Statistical tests
Testing for difference in proportions was performed using either the X 2 or Fisher's exact test.
All tests were two sided. P-values <0.05 were considered significant. 
RESULTS
Mutations
The mutations identified and the associated phenotypes are shown in table 1. In the entire cohort (140 patients from 124 families) we identified 36 EYA1 mutations in 42 families (55 patients), two SIX1 mutations and one SIX1 variant of unknown significance in 3 families (4 patients), but no SIX5 mutation. We identified two SIX5 variants which were not considered to be responsible for the phenotype: one was found in controls, and the other, previously reported as a disease causing mutation in two families (Hoskins et al., 2007) , was associated with a partial EYA1 deletion in one of these two families included in our cohort. Therefore, mutations were identified in 36% (45/124) of the tested families.
EYA1 gene analysis
Thirty-six EYA1 heterozygous mutations, spread over the entire length of the gene (figure 1), were identified in 42 probands (table 1) . Thirty-three were small mutations (8 missense including a mutation of the stop codon, 14 frameshift, 6 stop, and 5 splice-site mutations), and 24 of these were novel. All missense mutations but one [c.319G>A (p.Gly107Ser)] were considered as possibly or probably damaging by the PolyPhen software (http://genetics.bwh.harvard.edu/pph/). That mutation c.319G>A, which appeared de novo in the patient, was scored as benign by Polyphen but was in the last base of exon 4 and thus was expected to modify the splicing of intron 4 (GeneSplicer score changes from 6.97 to 2.49) .
Amino acid conservation scores according to ConSurf (varying from 1 to 9) for previously unpublished missense mutations are shown in table 1.Two previously reported mutations, c.982C>T and c.1220G>A, were respectively found in three and two unrelated patients. Three different deletions were identified in 5 unrelated patients by quantitative multiplex PCR amplification of short fluorescence fragments. In 3 of these probands (patients 608, 821, 991) all tested exons were missing and the deletion was considered to remove the entire gene. In 1  2  3  4  5  6  7  8  9  10  11  12  13  14  15  16  17  18  19  20  21  22  23  24  25  26  27  28  29  30  31  32  33  34  35  36  37  38  39  40  41  42  43  44  45  46  47  48  49  50  51  52  53  54  55  56  57  58  59 the other two cases, the deletion was partial and its precise extent was determined by MLPA analysis: one removed exons 8 to 16 (patient 1216) and one removed exons 3, 4 and 5 (patients 1062, 1063 and 1064). Patient 1062 was one of the 2 probands previously reported to carry the SIX5 p.Thr552Met mutation (patient A500 in Hoskins, et al., 2007) . Parent status was tested for 26 probands with an identified EYA1 mutation : 8 mutations out of 26 were de novo and 18 were inherited.
SIX1 gene analysis
Three different, potentially pathogenic variations in SIX1 were identified in 3 families (table   1) . The SIX1 mutation (p.Tyr129Cys) has already been described (Ruf et al., 2004) , and affects a conserved tyrosine in the homeodomain. It is predicted to be probably damaging by
Polyphen (score 2.945), and inhibits the transcription activation in vitro (Patrick et al., 2009) .
This mutation was also present in the affected father of the proband. The mutation c.560+3A>T, probably leading to aberrant splicing (GeneSplicer score changes from 9.74 to 2.89), has never been previously described. Finally, the c.746C>T change in exon 2 affects a strongly conserved amino acid (p.Pro249Leu) and was considered as possibly damaging by PolyPhen (score 1.806). Although this change was not present in 92 healthy control chromosomes it is located in a region of unknown function and replaces a non polar side chain amino acid with another amino acid of the same family. The segregation of these two last changes could not be tested because DNA samples from family members were not available.
SIX5 gene analysis
We did not identify any novel SIX5 mutations in our entire cohort. We confirmed the finding of the SIX5 p.Thr552Met heterozygous variant in patient 1062, and also found the same SIX5 affected. This variant was predicted as possibly damaging by the Polyphen program (score 1.711). However, we identified an EYA1 partial deletion in the three affected members of this family (see above). We found another SIX5 variant, c.156_161dup (p.Gly55Ala56dup), in a patient from Guadeloupe. That variant, which introduces two amino acids in the N-terminus of the protein, was also found in 3/86 controls from the West Indies and thus was considered as non pathogenic.
Phenotypes (tables 1 and 2)
According to previously described criteria In patients without any identified mutation, rare clinical features were also observed : palate or laryngeal anomalies (n=4), facial asymmetry (n=2) 
Genotype-phenotype correlation
Because the type and severity of the symptoms were very variable, we searched whether there was a correlation between the phenotype and either the mutated gene (EYA1 or SIX1) or the type of mutation (missense mutation, truncating mutation because of stop, frameshift, or splice-site mutation), or deletion. Of the 67 patients with typical BOR syndrome, 50 (75%), 1  2  3  4  5  6  7  8  9  10  11  12  13  14  15  16  17  18  19  20  21  22  23  24  25  26  27  28  29  30  31  32  33  34  35  36  37  38  39  40  41  42  43  44  45  46  47  48  49  50  51  52  53  54  55  56  57  58  59 (Table 3) .
Regarding the renal disease, cases with prenatal renal failure associated with oligoamnios (n=4) or with severe renal failure leading to renal transplant (n=5) were associated with SIX1 mutations in one case, and with EYA1 mutations in 7 cases. These proportions were not significantly different from that observed in all patients. However, in the 7 cases with EYA1 mutations, none of these mutations were a missense mutations (3 were frameshift, 1 splicesite, 1 stop and 2 were entire gene deletions).
DISCUSSION
To our knowledge, this study is the first one to analyze all of the genes currently known to be implicated in BOR syndrome in a large cohort of patients. Overall, we detected a mutation in 45/124 (36%) probands. Forty two probands were carrying an EYA1 mutation thought to be pathogenic. However, the impact of the c.867+5G>A change on mRNA splicing has not yet been demonstrated. Three probands were carrying mutations in SIX1. Of these, one (patient 714) was carrying the c.806C>T, p.Pro249Leu change, which has never been described before, and is predicted to be possibly damaging by Polyphen. This mutation was not found in 92 control chromosomes, but does not affect a protein domain with a known function. All other SIX1 mutations reported so far affect either the SIX or the homeodomain encoding nucleotides (Kochhar et al., 2008 , Ruf et al., 2004 . We were unable to test other family members of patients 714 and 715, so it is difficult to conclude whether this change is or not a disease-causing mutation.
In our entire cohort, we did not identify any pathogenic mutation in the SIX5 gene. In one patient previously reported to carry a SIX5 missense variant (case 1062), we found a partial (exons 3-5) EYA1 deletion. The three affected patients in this family were carrying both the EYA1 deletion and the SIX5 variant. We believe that the EYA1 deletion is responsible for the phenotype in this family, though we cannot rule out the hypothesis that the SIX5 variant may modify the EYA1-associated phenotype. However, whereas the three patients had deafness, the renal disease was more severe in the two siblings (undergoing renal transplantation at 22
and 23 years of age) than in their father (who had not reached end-stage renal failure at 58 years). This was despite the fact that all three carried the SIX5 variant. The finding of an EYA1 mutation in that family made us reconsider the role of SIX5 in the development of BOR syndrome. Among the 5 index cases reported by Hoskins et al. as carrying a SIX5 mutation (Hoskins et al., 2007) , all carried a missense variant, including two cases with the c.1655C>T p.Thr552Met variant (patient 1062 and another patient). The segregation of the variants with the phenotype had not been studied. These variants modestly (20 to 48%) although significantly decreased the ability of SIX5/EYA1 to activate gene transcription in vitro (Hoskins et al., 2007) . No other SIX5 mutation (whether missense or other type of mutation/rearrangment) has been reported since this initial report. In addition, whereas mice Among the patients that were classified with either typical or atypical BOR (122 patients), we identified a mutation in 75% of cases with typical BOR syndrome and in 9% of cases with atypical BOR syndrome. These results are different from those reported recently in a smaller cohort in which no mutations were detected in any subject with atypical BOR (Rickard et al., 2008) . This highlights the difficulty in reconciling the need for performing molecular testing in a consequential and cost effective manner, and the fact that a screening limited to typical BOR syndrome will miss few mutations and prevent accurate genetic counselling in these few families. The rate of mutation that we report here is not different from that recently reported in another large cohort . However, the rate of EYA1 deletion in the present study is lower than that (18%) reported by Chang et al. (Chang et al., 2004) . Although we used the same semiquantitative fluorescence multiplex PCR approach for tracking EYA1 deletions, we only tested exons 1, 5, 10, 15, and 16 in a first attempt. We may have thus missed small or complex deletions involving other exons.
In our series as in others , Ruf et al., 2004 , Saanggard et al., 2007 , Okada et al., Orten et al., 2008 , the type and severity of the phenotype does not seem to correlate with the type of mutation and is very variable, even within a given family. Only the severity of renal failure may correlate to some extent with the type of EYA1 mutation, as none of the 7 patients with the most severe renal insufficiency were carrying a missense mutation. However the small number of patients does not allow any conclusion to be made, and it would be interesting to analyze the severity of the renal failure in a larger number of cases carrying an EYA1 mutation. The high frequency of renal anomalies in our series may be due to the fact We report some interesting clinical features associated with EYA1 mutations. Although already reported by others (Chen et al., 1995 , Shimasaki et al., 2004 ) the association with hypothyroidism or with persistent ductus arteriosus may be fortuitous, as may be the association with a conotruncal cardiopathy. Two patients suffered from cataract, which could be associated with a defect of early expression of EYA1 in the anterior ocular segment, and has already been described (Azuma et al., 2000) . A facial nerve impairment was present in six patients, which may be explained by anomalies of inner ear, affecting the nerve trajectory.
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